Cargando…

Open field study on the efficacy of oral fluralaner for long-term control of flea allergy dermatitis in client-owned dogs in Ile-de-France region

BACKGROUND: Fluralaner is the first orally administered isoxazoline to provide 12 weeks of activity against fleas and ticks after a single administration. As a result of its potent anti-flea activity, oral fluralaner may be proposed as a component of a strategy for the control of flea allergy dermat...

Descripción completa

Detalles Bibliográficos
Autores principales: Crosaz, Odile, Chapelle, Elodie, Cochet-Faivre, Noëlle, Ka, Diane, Hubinois, Céline, Guillot, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806425/
https://www.ncbi.nlm.nih.gov/pubmed/27007494
http://dx.doi.org/10.1186/s13071-016-1463-z
_version_ 1782423234069659648
author Crosaz, Odile
Chapelle, Elodie
Cochet-Faivre, Noëlle
Ka, Diane
Hubinois, Céline
Guillot, Jacques
author_facet Crosaz, Odile
Chapelle, Elodie
Cochet-Faivre, Noëlle
Ka, Diane
Hubinois, Céline
Guillot, Jacques
author_sort Crosaz, Odile
collection PubMed
description BACKGROUND: Fluralaner is the first orally administered isoxazoline to provide 12 weeks of activity against fleas and ticks after a single administration. As a result of its potent anti-flea activity, oral fluralaner may be proposed as a component of a strategy for the control of flea allergy dermatitis (FAD) in dogs. The open field study reported here assessed the efficacy of fluralaner for long-term control (up to 6 months) of FAD in affected client-owned dogs maintained under common household conditions in the Ile-de-France region. METHODS: This was an open pre-treatment versus post-treatment study. Client-owned dogs with clinical signs of FAD were recruited and treated with oral fluralaner (Bravecto®) at 25-56 mg/kg body weight on days 0 and 84. The dogs’ condition was assessed at each visit (on days 0, 28, 84 and 168) using the following three parameters: (i) extent of skin lesions based on the scoring system for canine FAD; (ii) pruritus severity based on the pruritus visual analog scale; (iii) presence or absence of fleas or flea feces. RESULTS: Of the 26 dogs initially enrolled, 23 were presented on day 28, 20 on day 84 and 16 for the final evaluation on day 168. Eighteen out of 20 dogs (90 %) presented on day 84 and 15 out of 16 dogs (94 %) presented on day 168 showed a complete clinical resolution. The post-treatment FAD clinical scores on days 28, 84 and 168 were significantly different from that of the pre-treatment with a reduction of 89.8 %, 98.8 % and 99.8 %, respectively. The post-treatment pruritus index values on days 28, 84 and 168 were significantly different from that of the pre-treatment with a reduction of 45.2 %, 71.2 % and 80.8 %, respectively. CONCLUSIONS: The present study confirmed that oral fluralaner treatment should be considered as effective for long-term control of clinical signs in FAD affected dogs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13071-016-1463-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4806425
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48064252016-03-24 Open field study on the efficacy of oral fluralaner for long-term control of flea allergy dermatitis in client-owned dogs in Ile-de-France region Crosaz, Odile Chapelle, Elodie Cochet-Faivre, Noëlle Ka, Diane Hubinois, Céline Guillot, Jacques Parasit Vectors Research BACKGROUND: Fluralaner is the first orally administered isoxazoline to provide 12 weeks of activity against fleas and ticks after a single administration. As a result of its potent anti-flea activity, oral fluralaner may be proposed as a component of a strategy for the control of flea allergy dermatitis (FAD) in dogs. The open field study reported here assessed the efficacy of fluralaner for long-term control (up to 6 months) of FAD in affected client-owned dogs maintained under common household conditions in the Ile-de-France region. METHODS: This was an open pre-treatment versus post-treatment study. Client-owned dogs with clinical signs of FAD were recruited and treated with oral fluralaner (Bravecto®) at 25-56 mg/kg body weight on days 0 and 84. The dogs’ condition was assessed at each visit (on days 0, 28, 84 and 168) using the following three parameters: (i) extent of skin lesions based on the scoring system for canine FAD; (ii) pruritus severity based on the pruritus visual analog scale; (iii) presence or absence of fleas or flea feces. RESULTS: Of the 26 dogs initially enrolled, 23 were presented on day 28, 20 on day 84 and 16 for the final evaluation on day 168. Eighteen out of 20 dogs (90 %) presented on day 84 and 15 out of 16 dogs (94 %) presented on day 168 showed a complete clinical resolution. The post-treatment FAD clinical scores on days 28, 84 and 168 were significantly different from that of the pre-treatment with a reduction of 89.8 %, 98.8 % and 99.8 %, respectively. The post-treatment pruritus index values on days 28, 84 and 168 were significantly different from that of the pre-treatment with a reduction of 45.2 %, 71.2 % and 80.8 %, respectively. CONCLUSIONS: The present study confirmed that oral fluralaner treatment should be considered as effective for long-term control of clinical signs in FAD affected dogs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13071-016-1463-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-03-23 /pmc/articles/PMC4806425/ /pubmed/27007494 http://dx.doi.org/10.1186/s13071-016-1463-z Text en © Crosaz et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Crosaz, Odile
Chapelle, Elodie
Cochet-Faivre, Noëlle
Ka, Diane
Hubinois, Céline
Guillot, Jacques
Open field study on the efficacy of oral fluralaner for long-term control of flea allergy dermatitis in client-owned dogs in Ile-de-France region
title Open field study on the efficacy of oral fluralaner for long-term control of flea allergy dermatitis in client-owned dogs in Ile-de-France region
title_full Open field study on the efficacy of oral fluralaner for long-term control of flea allergy dermatitis in client-owned dogs in Ile-de-France region
title_fullStr Open field study on the efficacy of oral fluralaner for long-term control of flea allergy dermatitis in client-owned dogs in Ile-de-France region
title_full_unstemmed Open field study on the efficacy of oral fluralaner for long-term control of flea allergy dermatitis in client-owned dogs in Ile-de-France region
title_short Open field study on the efficacy of oral fluralaner for long-term control of flea allergy dermatitis in client-owned dogs in Ile-de-France region
title_sort open field study on the efficacy of oral fluralaner for long-term control of flea allergy dermatitis in client-owned dogs in ile-de-france region
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806425/
https://www.ncbi.nlm.nih.gov/pubmed/27007494
http://dx.doi.org/10.1186/s13071-016-1463-z
work_keys_str_mv AT crosazodile openfieldstudyontheefficacyoforalfluralanerforlongtermcontroloffleaallergydermatitisinclientowneddogsiniledefranceregion
AT chapelleelodie openfieldstudyontheefficacyoforalfluralanerforlongtermcontroloffleaallergydermatitisinclientowneddogsiniledefranceregion
AT cochetfaivrenoelle openfieldstudyontheefficacyoforalfluralanerforlongtermcontroloffleaallergydermatitisinclientowneddogsiniledefranceregion
AT kadiane openfieldstudyontheefficacyoforalfluralanerforlongtermcontroloffleaallergydermatitisinclientowneddogsiniledefranceregion
AT hubinoisceline openfieldstudyontheefficacyoforalfluralanerforlongtermcontroloffleaallergydermatitisinclientowneddogsiniledefranceregion
AT guillotjacques openfieldstudyontheefficacyoforalfluralanerforlongtermcontroloffleaallergydermatitisinclientowneddogsiniledefranceregion